BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
2 Chen J. The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis. PLoS One 2018;13:e0200909. [PMID: 30102707 DOI: 10.1371/journal.pone.0200909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy 2014;9:1499-510. [DOI: 10.1586/era.09.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
4 Tan J, Zhao C, Peng N, Yang Y, Zhong J, Yang T, Zheng M, Wang Y, Gong W, Xiang B, Li L. Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection: Association of Age and Outcome Among HCC. J Surg Oncol 2016;114:966-70. [DOI: 10.1002/jso.24434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
5 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
6 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Reference Citation Analysis]
7 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
8 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chen VL, Parikh ND. Liquid Biopsy for Hepatocellular Carcinoma. Curr Hepatology Rep 2019;18:390-9. [DOI: 10.1007/s11901-019-00491-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Xie C, Huang L, Xie S, Xie D, Zhang G, Wang P, Peng L, Gao Z. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J Transl Med 2013;11:272. [PMID: 24159927 DOI: 10.1186/1479-5876-11-272] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
11 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
12 Wei L, Dai Y, Zhou Y, He Z, Yao J, Zhao L, Guo Q, Yang L. Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. Cell Death Dis 2017;8:e2944. [PMID: 28726775 DOI: 10.1038/cddis.2017.335] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
13 Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27:553-561. [PMID: 21913982 DOI: 10.1111/j.1440-1746.2011.06910.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 11.0] [Reference Citation Analysis]
14 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Huo TI. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther. 2012;36:551-559. [PMID: 22817677 DOI: 10.1111/j.1365-2036.2012.05226.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
15 Holliday EB, Allen PK, Elhalawani H, Abdel-rahman O. Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma. Liver Int 2018;38:665-75. [DOI: 10.1111/liv.13561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Zhang N, Hu Z, Qiang Y, Zhu X. Circulating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Mol Genet Genomic Med. 2019;7:e1012. [PMID: 31660696 DOI: 10.1002/mgg3.1012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
17 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol. 2017;43:32-41. [PMID: 27283892 DOI: 10.1016/j.ejso.2016.05.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
19 Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9:1628-1632. [PMID: 25789012 DOI: 10.3892/ol.2015.2960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
20 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
21 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
22 Zhang Y, Fan W, Wang Y, Huang G, Li J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control. 2019;26:1073274819872216. [PMID: 31466465 DOI: 10.1177/1073274819872216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
23 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Reference Citation Analysis]
24 Zhou L, Rui JA, Zhou WX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio. Pathol Res Pract 2017;213:824-30. [PMID: 28554743 DOI: 10.1016/j.prp.2017.03.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
25 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
26 Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 2021;124:1388-97. [PMID: 33531690 DOI: 10.1038/s41416-021-01260-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, Lin HC, Huo TI. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48:734-41. [PMID: 24100755 DOI: 10.1097/MCG.0b013e3182a8a254] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
28 Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schöb O, Giryes A, Abdel-Rahman O. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol 2017;11:695-701. [PMID: 28276812 DOI: 10.1080/17474124.2017.1294485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
29 Han G, Zhao Y, Qi X, Fan D. Hepatocellular carcinoma treated with sorafenib: Invited Commentaries. Alimentary Pharmacology & Therapeutics 2011;34:1347-8. [DOI: 10.1111/j.1365-2036.2011.04852.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
32 Huo TI, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Chiang JH, Lee PC, Lee SD. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146. [PMID: 21194431 DOI: 10.1186/1471-230X-10-146] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
33 Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee SG. The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. J Gastrointest Surg. 2015;19:1281-1290. [PMID: 25956724 DOI: 10.1007/s11605-015-2849-5] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
34 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945 [PMID: 25945007 DOI: 10.3748/wjg.v21.i16.4933] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
36 Rich NE, Yopp AC, Singal AG. Medical Management of Hepatocellular Carcinoma. JOP 2017;13:356-64. [DOI: 10.1200/jop.2017.022996] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
37 Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018;9:37721-37732. [PMID: 30701027 DOI: 10.18632/oncotarget.26507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Jin Y, Liang Z, Zhou W, Zhou L. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection. Journal of Investigative Surgery 2017;31:412-9. [DOI: 10.1080/08941939.2017.1347218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Lin SB, Zhou L, Liang ZY, Zhou WX, Jin Y. Expression of GRK2 and IGF1R in hepatocellular carcinoma: clinicopathological and prognostic significance. J Clin Pathol 2017;70:754-9. [PMID: 28202495 DOI: 10.1136/jclinpath-2016-203998] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
40 d'Abadie P, Hesse M, Jamar F, Lhommel R, Walrand S. 90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol 2018;63:245010. [PMID: 30524029 DOI: 10.1088/1361-6560/aaf205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
41 Obiorah IE, Chahine J, Ko K, Park BU, deGuzman J, Kallakury B. Prognostic Implications of Arginase and Cytokeratin 19 Expression in Hepatocellular Carcinoma After Curative Hepatectomy: Correlation With Recurrence-Free Survival. Gastroenterology Res 2019;12:78-87. [PMID: 31019617 DOI: 10.14740/gr1156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
42 Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, Liu CJ, Lin CL, Yu MW. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012;131:2612-2621. [PMID: 22362517 DOI: 10.1002/ijc.27508] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
43 Zhou Y, Liu L, Liu Y, Zhou P, Yan Q, Yu H, Chen X, Zhu F. Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell Death Discov 2021;7:177. [PMID: 34238921 DOI: 10.1038/s41420-021-00562-5] [Reference Citation Analysis]
44 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [DOI: 10.1002/hep.27443] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 12.4] [Reference Citation Analysis]
45 Zhang Y, Huang G, Miao H, Song Z, Zhang X, Fan W, Wang Y, Li J, Chen Y. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920937422. [PMID: 32754228 DOI: 10.1177/1758835920937422] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, Poyanli A, Gulluoglu M, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol 2018; 10(1): 51-61 [PMID: 29399278 DOI: 10.4254/wjh.v10.i1.51] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Liu W, Wang N, Lu M, Du XJ, Xing BC. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. Mol Med Rep 2016;14:1617-23. [PMID: 27315121 DOI: 10.3892/mmr.2016.5404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
48 Jin Y, Liang ZY, Zhou WX, Zhou L. Expression and Significances of G-Protein-Coupled Receptor Kinase 3 in Hepatocellular Carcinoma. J Cancer 2017;8:1972-8. [PMID: 28819396 DOI: 10.7150/jca.19201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
50 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 13.8] [Reference Citation Analysis]
51 Wu T, Ma XA, Wang GQ, Li Q, Li MJ, Guo JY, Liang X, Ruan ZP, Tian T, Nan KJ, Liu LN, Guo H. ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy. Sci Rep 2017;7:4412. [PMID: 28667286 DOI: 10.1038/s41598-017-04046-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int. 2010;30:479-486. [PMID: 20040053 DOI: 10.1111/j.1478-3231.2009.02191.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
53 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
54 Wan T, Zhang T, Si X, Zhou Y. Overexpression of EMT-inducing transcription factors as a potential poor prognostic factor for hepatocellular carcinoma in Asian populations: A meta-analysis. Oncotarget 2017;8:59500-8. [PMID: 28938653 DOI: 10.18632/oncotarget.18352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
55 Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol. 2013;24:406-411. [PMID: 23041587 DOI: 10.1093/annonc/mds343] [Cited by in Crossref: 74] [Cited by in F6Publishing: 81] [Article Influence: 8.2] [Reference Citation Analysis]
56 Mähringer-Kunz A, Meyer FI, Hahn F, Müller L, Düber C, Pinto Dos Santos D, Galle PR, Weinmann A, Kloeckner R, Schotten S. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterol J 2021;9:590-7. [PMID: 34077613 DOI: 10.1002/ueg2.12098] [Reference Citation Analysis]
57 Zhou L, Rui J, Wang S, Chen S, Qu Q. Clinicopathological Predictors of Poor Survival and Recurrence After Curative Resection in Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis. Pathol Oncol Res 2015;21:131-8. [DOI: 10.1007/s12253-014-9798-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
58 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 19.3] [Reference Citation Analysis]
59 Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57:1013-1020. [PMID: 22732513 DOI: 10.1016/j.jhep.2012.06.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 12.6] [Reference Citation Analysis]
60 Zeng J, Lin K, Liu H, Huang Y, Guo P, Zeng Y, Zeng J, Liu J. Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study. Cancer Manag Res 2020;12:6597-606. [PMID: 32848453 DOI: 10.2147/CMAR.S261368] [Reference Citation Analysis]
61 Caetano Oliveira R, Martins R, Abrantes AM, Jesus Â, Teixeira P, Canhoto C, Guerreiro P, Costa B, Silva MR, Tralhão JG, Cipriano MA. Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome-Implications on Patient Selection. J Gastrointest Surg 2021;25:698-707. [PMID: 32410177 DOI: 10.1007/s11605-020-04611-9] [Reference Citation Analysis]
62 Attallah AM, Omran MM, Attallah AA, Abdelrazek MA, Farid K, El-dosoky I. Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol 2017;22:332-9. [DOI: 10.1007/s10147-016-1066-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
63 Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma. Epidemiology 2013;24:671-81. [PMID: 23788213 DOI: 10.1097/EDE.0b013e31829d2744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
64 Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 2011;15:1433-1439. [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
65 Huang XY, Yao JG, Huang HD, Wang C, Ma Y, Xia Q, Long XD. MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis. Gastroenterol Res Pract 2013;2013:804128. [PMID: 24204382 DOI: 10.1155/2013/804128] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
66 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283. [PMID: 20112254 DOI: 10.1002/hep.23485] [Cited by in Crossref: 249] [Cited by in F6Publishing: 230] [Article Influence: 22.6] [Reference Citation Analysis]
67 Lee CW, Yu MC, Lin G, Chiu JC, Chiang MH, Sung CM, Hsieh YC, Kuo T, Lin CY, Tsai HI. Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study. World J Surg Oncol 2020;18:121. [PMID: 32493393 DOI: 10.1186/s12957-020-01885-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Wang WL, Zheng XL, Zhang ZY, Zhou Y, Hao J, Tang G, Li O, Xiang JX, Wu Z, Wang B. Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection. Medicine (Baltimore) 2016;95:e4087. [PMID: 27399101 DOI: 10.1097/MD.0000000000004087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
69 op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One. 2012;7:e45066. [PMID: 23071507 DOI: 10.1371/journal.pone.0045066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
70 Blank S, Wang Q, Fiel MI, Luan W, Kim KW, Kadri H, Mandeli J, Hiotis SP. Assessing prognostic significance of preoperative alpha-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol. 2014;21:986-994. [PMID: 24232510 DOI: 10.1245/s10434-013-3357-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
71 Pompili M, Saviano A, de Matthaeis N, Cucchetti A, Ardito F, Federico B, Brunello F, Pinna AD, Giorgio A, Giulini SM, De Sio I, Torzilli G, Fornari F, Capussotti L, Guglielmi A, Piscaglia F, Aldrighetti L, Caturelli E, Calise F, Nuzzo G, Rapaccini GL, Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey. Journal of Hepatology 2013;59:89-97. [DOI: 10.1016/j.jhep.2013.03.009] [Cited by in Crossref: 160] [Cited by in F6Publishing: 159] [Article Influence: 20.0] [Reference Citation Analysis]
72 Yopp AC, Parikh ND, Singal AG. Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System? Clinical Gastroenterology and Hepatology 2017;15:756-8. [DOI: 10.1016/j.cgh.2016.12.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Oncotarget 2015;6:41383-97. [PMID: 26515591 DOI: 10.18632/oncotarget.5510] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
74 Zhang TT, Zhao XQ, Liu Z, Mao ZY, Bai L. Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. Clin Transl Oncol. 2016;18:831-840. [PMID: 26577107 DOI: 10.1007/s12094-015-1446-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
75 Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45:408-413. [PMID: 23182599 DOI: 10.1016/j.dld.2012.10.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
76 Sun Y, Bai H, Xia W, Wang D, Zhou B, Zhao X, Yang G, Xu L, Zhang W, Liu P, Xu J, Meng S, Liu R, Gao X. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. J Magn Reson Imaging 2020;52:1083-90. [PMID: 32233054 DOI: 10.1002/jmri.27143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
77 Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer 2013;109:1657-65. [PMID: 23982602 DOI: 10.1038/bjc.2013.481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
78 Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med 2019;8:928-38. [PMID: 30701703 DOI: 10.1002/cam4.1948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
79 Li YC, Chen PH, Yeh JH, Hsiao P, Lo GH, Tan T, Cheng PN, Lin HY, Chen YS, Hsieh KC, Hsieh PM, Lin CW. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:418. [PMID: 34749663 DOI: 10.1186/s12876-021-01995-z] [Reference Citation Analysis]
80 Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Maria Pellicelli A, Delle Fave G, Marignani M. Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. Annals of Hepatology 2017;16:107-14. [DOI: 10.5604/16652681.1226821] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
81 Park GC, Hwang S, Park YH, Choi JU; Korean Liver Cancer Study Group. Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database. Ann Surg Treat Res 2020;98:235-46. [PMID: 32411628 DOI: 10.4174/astr.2020.98.5.235] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H, Audrain O, Rolland Y, Clément B, Raoul JL, Garin E. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol. 2013;2013:827649. [PMID: 23476792 DOI: 10.1155/2013/827649] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
83 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
84 Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int 2018;38:885-94. [PMID: 28941130 DOI: 10.1111/liv.13593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
85 Hao S, Chen S, Yang X, Wan C. Adverse impact of intermittent portal clamping on long-term postoperative outcomes in hepatocellular carcinoma. Ann R Coll Surg Engl 2017;99:22-7. [PMID: 27269234 DOI: 10.1308/rcsann.2016.0183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
86 Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, Liu Y, Liu H, Yang X, Wang R. Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2017;17:91. [PMID: 28143427 DOI: 10.1186/s12885-017-3062-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
87 Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, Loong CC, Chiang JH, Chiou YY, Lee SD. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010;30:198-207. [PMID: 19849777 DOI: 10.1111/j.1478-3231.2009.02143.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
88 Zakaria HM, Macshut M, Gaballa NK, Sherif AE, Abdel-Samea ME, Abdel-Samiee M, Marwan I, Yassein T. Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study. Ann Med Surg (Lond) 2020;54:47-53. [PMID: 32368340 DOI: 10.1016/j.amsu.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18: 2879-2902. e9. [PMID: 32289533 DOI: 10.1016/j.cgh.2020.04.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
90 Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009;50:601-612. [PMID: 19881961 DOI: 10.3349/ymj.2009.50.5.601] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
91 Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24(15): 1641-1649 [PMID: 29686471 DOI: 10.3748/wjg.v24.i15.1641] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
92 Bai K, Cao Y, Huang C, Chen J, Zhang X, Jiang Y. Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore) 2016;95:e2493. [PMID: 26765460 DOI: 10.1097/MD.0000000000002493] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
93 Sato N, Marubashi S. What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection? Surg Today 2021. [PMID: 34392420 DOI: 10.1007/s00595-021-02352-z] [Reference Citation Analysis]
94 Yang Z, Yang Y, Zhou G, Luo Y, Yang W, Zhou Y, Yang J. The Prediction of Survival in Hepatocellular Carcinoma Based on A Four Long Non-coding RNAs Expression Signature. J Cancer 2020;11:4132-44. [PMID: 32368296 DOI: 10.7150/jca.40621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Wu S, Zhang Z, Cheng N, Xiong X, Yang L. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. Surgical Oncology 2019;29:159-67. [DOI: 10.1016/j.suronc.2019.05.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
96 Gan W, Yi Y, Fu Y, Huang J, Lu Z, Jing C, Fan J, Zhou J, Qiu S. Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. J Cancer 2018;9:148-56. [PMID: 29290780 DOI: 10.7150/jca.22246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
97 Mgaieth S, Kemp W, Gow P, Fink M, Lubel J, Nicoll A, Gazzola A, Hong T, Ryan M, Knight V, Dev AT, Sood S, Bell S, Paul E, Roberts SK. Impact of viral hepatitis aetiology on survival outcomes in hepatocellular carcinoma: A large multicentre cohort study. J Viral Hepat 2017;24:982-9. [PMID: 28414893 DOI: 10.1111/jvh.12717] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
98 Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembé AB, Ikeda M. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci 2016;107:1791-9. [PMID: 27627050 DOI: 10.1111/cas.13077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
99 Kwak MS, Lee JH, Yoon JH, Yu SJ, Cho EJ, Jang ES, Kim YJ, Lee HS. Risk factors, clinical features, and prognosis of the hepatocellular carcinoma with peritoneal metastasis. Dig Dis Sci. 2012;57:813-819. [PMID: 22147252 DOI: 10.1007/s10620-011-1995-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
100 Chen W, Zhang Z, Fang X, Xiong L, Wen Y, Zhou J, Kong F, Zou H. Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion. Medicine (Baltimore) 2021;100:e26265. [PMID: 34128857 DOI: 10.1097/MD.0000000000026265] [Reference Citation Analysis]
101 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 164] [Article Influence: 38.3] [Reference Citation Analysis]
102 Liu L, Zhang C, Zhao Y, Qi X, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. Biomed Res Int. 2014;2014:194278. [PMID: 24800212 DOI: 10.1155/2014/194278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
103 Lee WC, Chou HS, Wu TJ, Lee CF, Hsu PY, Hsu HY, Wu TH, Chan KM. Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis. Clin Proteomics 2017;14:29. [PMID: 28785178 DOI: 10.1186/s12014-017-9164-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
104 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:68-73. [PMID: 23392801 DOI: 10.1016/s1499-3872(13)60008-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
105 Li T, Qin LX, Gong X, Zhou J, Sun HC, Wang L, Qiu SJ, Ye QH, Fan J. Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence of female patients after curative resection of hepatocellular carcinoma. Surgery 2014;156:651-60. [PMID: 24998159 DOI: 10.1016/j.surg.2014.04.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
106 Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Value Health 2017;20:336-44. [PMID: 28292478 DOI: 10.1016/j.jval.2016.09.2397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
107 Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Yeoh EM, Ye SL. Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer 2010;10:620. [PMID: 21062497 DOI: 10.1186/1471-2407-10-620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
108 Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, Wang H, An LJ, Xu ZX, Wang CP. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11:41. [PMID: 23414367 DOI: 10.1186/1479-5876-11-41] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
109 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI, Lee SD. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2013;7:645-54. [PMID: 26201797 DOI: 10.1007/s12072-012-9375-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
110 Xie C, Wu J, Yun J, Lai J, Yuan Y, Gao Z, Li M, Li J, Song L. MACC1 as a prognostic biomarker for early-stage and AFP-normal hepatocellular carcinoma. PLoS One 2013;8:e64235. [PMID: 23717574 DOI: 10.1371/journal.pone.0064235] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
111 Xu XS, Chen W, Miao RC, Zhou YY, Wang ZX, Zhang LQ, Qu K, Pang Q, Wang RT, Liu C. Survival Analysis of Hepatocellular Carcinoma: A Comparison Between Young Patients and Aged Patients. Chin Med J (Engl) 2015;128:1793-800. [PMID: 26112722 DOI: 10.4103/0366-6999.159356] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
112 Hung HH, Chiou YY, Hsia CY, Su CW, Chou YH, Chiang JH, Kao WY, Huo TI, Huang YH, Su YH. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79-86. [PMID: 20831902 DOI: 10.1016/j.cgh.2010.08.018] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 9.6] [Reference Citation Analysis]
113 Lee CW, Tsai HI, Lee WC, Huang SW, Lin CY, Hsieh YC, Kuo T, Chen CW, Yu MC. Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal? J Clin Med 2019;8:E1736. [PMID: 31635078 DOI: 10.3390/jcm8101736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
114 Lencioni R, Kudo M, Ye S, Bronowicki J, Chen X, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study: First interim analysis of the GIDEON study. International Journal of Clinical Practice 2012;66:675-83. [DOI: 10.1111/j.1742-1241.2012.02940.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 8.7] [Reference Citation Analysis]
115 Lu LH, Zhang YF, Wei W, Shi M, Guo RP. Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. J Gastrointest Surg. 2017;21:2025-2032. [PMID: 28840443 DOI: 10.1007/s11605-017-3528-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
116 Choi JH, Hwang S, Lee YJ, Kim KH, Ko GY, Gwon DI, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee SG. Prognostic effect of preoperative sequential transcatheter arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2015;19:59-65. [PMID: 26155278 DOI: 10.14701/kjhbps.2015.19.2.59] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
117 Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. Med Oncol 2017;34:192. [PMID: 29098441 DOI: 10.1007/s12032-017-1040-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
118 Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int 2020;40:947-55. [PMID: 31943689 DOI: 10.1111/liv.14379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
119 El-mezayen HA, Darwish H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumour Biol 2014;35:6501-9. [PMID: 24687551 DOI: 10.1007/s13277-014-1858-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
120 Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Jung DH, Park GC, Lee SG. Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma. J Gastrointest Surg 2016;20:1807-20. [PMID: 27311982 DOI: 10.1007/s11605-016-3187-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
121 Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3843-3849 [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
122 Kang HY, Shin HD, Kim SB, Song IH. Prognosis predictability of hepatocellular carcinoma according to staging systems in hepatitis B virus-endemic area. Clin Res Hepatol Gastroenterol 2012;36:357-64. [PMID: 22326248 DOI: 10.1016/j.clinre.2011.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol 2018;12:515-23. [PMID: 29543072 DOI: 10.1080/17474124.2018.1453806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
124 Li JD, Xu XF, Han J, Wu H, Xing H, Li C, Yu JJ, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Lau WY, Wu MC, Shen F, Yang T. Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21:157-166. [PMID: 30082212 DOI: 10.1016/j.hpb.2018.06.1803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
125 Hao S, Chen S, Yang X, Wan C. Impact of intermittent portal clamping on the early recurrence of hepatocellular carcinoma after surgery. Surg Today 2016;46:1290-5. [DOI: 10.1007/s00595-016-1316-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
126 Yang T, Zhu J, Zhao L, Mai K, Ye J, Huang S, Zhao Y. Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. J Surg Oncol. 2017;115:718-728. [PMID: 28127774 DOI: 10.1002/jso.24549] [Cited by in Crossref: 22] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
127 Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Loong CC, Chiou YY, Huo TI. Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis 2012;44:868-74. [PMID: 22647396 DOI: 10.1016/j.dld.2012.04.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
128 Asrih M, Lenglet S, Mach F, Montecucco F. Alpha-fetoprotein: A controversial prognostic biomarker for small hepatocellular carcinoma. World J Gastroenterol 2013; 19(3): 328-330 [PMID: 23372353 DOI: 10.3748/wjg.v19.i3.328] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
129 Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802-1829. [PMID: 19455106 DOI: 10.1038/ajg.2009.191] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 14.0] [Reference Citation Analysis]
130 Di Costanzo GG, Signoriello S, Tortora R, Gallo C. A prognostic index for patients within the intermediate stage of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2016;28:592-8. [DOI: 10.1097/meg.0000000000000562] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
131 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
132 Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One 2019;14:e0219469. [PMID: 31291332 DOI: 10.1371/journal.pone.0219469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lee KC. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789-795. [PMID: 22941428 DOI: 10.1097/mcg.0b013e31825ceeb5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
134 Lu LH, Zhang YF, Mu-Yan C, Kan A, Zhong XP, Mei J, Ling YH, Li SH, Shi M, Wei W, Guo RP. Platelet-albumin-bilirubin grade: Risk stratification of liver failure, prognosis after resection for hepatocellular carcinoma. Dig Liver Dis. 2019;51:1430-1437. [PMID: 31054962 DOI: 10.1016/j.dld.2019.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
135 Hamada T, Yano K, Wada T, Imamura N, Hiyoshi M, Kondo K, Nanashima A. Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. World J Surg 2020;44:2770-6. [PMID: 32318792 DOI: 10.1007/s00268-020-05527-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Li M, Zhao Y, Liu X, Dang Z, Wang X, Jiang Y, Yang Z. Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett 2019;17:119-26. [PMID: 30655746 DOI: 10.3892/ol.2018.9590] [Reference Citation Analysis]
137 Fu YP, Yi Y, Huang JL, Jing CY, Sun J, Ni XC, Lu ZF, Cao Y, Zhou J, Fan J, Qiu SJ. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. Oncologist 2017;22:561-9. [PMID: 28438885 DOI: 10.1634/theoncologist.2016-0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
138 Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371-1379. [PMID: 22535689 DOI: 10.1002/hep.25814] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 9.6] [Reference Citation Analysis]
139 Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci 2019;24:86. [PMID: 31741658 DOI: 10.4103/jrms.JRMS_1017_18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
140 Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. [PMID: 24745023 DOI: 10.1155/2014/741465] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
141 Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget. 2016;7:45283-45301. [PMID: 27304193 DOI: 10.18632/oncotarget.9942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 17.7] [Reference Citation Analysis]
142 Johnson PJ, Dhanaraj S, Berhane S, Bonnett L, Ma YT. The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study. Br J Cancer 2021;125:714-6. [PMID: 34127809 DOI: 10.1038/s41416-021-01445-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
144 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
145 van den Berg T, Heymans MW, Leone SS, Vergouw D, Hayden JA, Verhagen AP, de Vet HC. Overview of data-synthesis in systematic reviews of studies on outcome prediction models. BMC Med Res Methodol 2013;13:42. [PMID: 23497181 DOI: 10.1186/1471-2288-13-42] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
146 Cheng Z, Yang P, Lei Z, Zhang B, Si A, Yan Z, Xia Y, Li J, Wang K, Hartmann D, Hüser N, Lau WY, Shen F. Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. Surgery 2017;162:1231-40. [PMID: 29033225 DOI: 10.1016/j.surg.2017.07.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
147 Chatterley T, Dennett L. Utilisation of search filters in systematic reviews of prognosis questions. Health Info Libr J 2012;29:309-22. [PMID: 23176027 DOI: 10.1111/hir.12004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
148 Mulé S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib. Radiology 2018;288:445-55. [PMID: 29584597 DOI: 10.1148/radiol.2018171320] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
149 Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N, Koike K. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350-360. [PMID: 24929638 DOI: 10.1007/s00535-014-0973-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 13.9] [Reference Citation Analysis]
150 Shen Q, Yang XR, Tan Y, You H, Xu Y, Chu W, Ge T, Zhou J, Qiu SJ, Shi YH, Zhang Z, Gu J, Wang H, Fan J, Qin W. High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. Hepat Oncol 2015;2:231-44. [PMID: 30191005 DOI: 10.2217/hep.15.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
151 Abdelaziz AO, Shousha HI, Abdelmaksoud AH, Saad Y, Elbaz TM, Soliman ZA, Salah A, Lithy R, Ahmed M, Nabil MM. A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2018;30:514-9. [PMID: 29465472 DOI: 10.1097/MEG.0000000000001085] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
152 Huang GQ, Zhu GQ, Huang S, You J, Shi KQ, Hu B, Ruan LY, Zhou MT, Braddock M, Zheng MH. Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. Expert Rev Gastroenterol Hepatol 2015;9:1127-38. [PMID: 26186642 DOI: 10.1586/17474124.2015.1057503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
153 Qi X, Guo X. Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. Prz Gastroenterol. 2015;10:142-147. [PMID: 26516379 DOI: 10.5114/pg.2015.52470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
154 Mao Z, Mo X, Qin C, Lai Y, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review: Course and prognosis of MG. European Journal of Neurology 2010;17:913-21. [DOI: 10.1111/j.1468-1331.2010.03017.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
155 Shi G, Han X, Wang Q, Ding Y, Liu H, Zhang Y, Dai Y. Evaluation of Multiple Prognostic Factors of Hepatocellular Carcinoma with Intra-Voxel Incoherent Motions Imaging by Extracting the Histogram Metrics. Cancer Manag Res 2020;12:6019-31. [PMID: 32765101 DOI: 10.2147/CMAR.S262973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
156 Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, Sueyoshi H, Takada R, Fukutake N, Uehara H, Ashida R, Ioka T, Nakazawa T, Nakanishi K, Katayama K. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int. 2017;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
157 Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg. 2013;37:608-613. [PMID: 23188538 DOI: 10.1007/s00268-012-1866-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
158 Shiba H, Horiuchi T, Sakamoto T, Furukawa K, Shirai Y, Iida T, Fujiwara Y, Haruki K, Yanaga K. Glasgow prognostic score predicts therapeutic outcome after hepatic resection for hepatocellular carcinoma. Oncol Lett 2017;14:293-8. [PMID: 28693167 DOI: 10.3892/ol.2017.6104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
159 Kim NG, Nguyen PP, Dang H, Kumari R, Garcia G, Esquivel CO, Nguyen MH. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015: Long-Term Survival in Patients With HCC. Cancer 2018;124:2588-98. [DOI: 10.1002/cncr.31373] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
160 Tateishi R, Fujiwara N. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 195-224. [DOI: 10.1007/978-3-030-21540-8_10] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Suzuki E, Ooka Y, Chiba T, Kobayashi K, Kanogawa N, Motoyama T, Saito T, Ogasawara S, Tawada A, Yokosuka O. Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clin J Gastroenterol 2015;8:41-6. [PMID: 25481841 DOI: 10.1007/s12328-014-0542-y] [Reference Citation Analysis]
162 Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW. Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis. J Vasc Interv Radiol. 2015;26:651-659. [PMID: 25824316 DOI: 10.1016/j.jvir.2015.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
163 Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N. Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549-4558. [PMID: 29435123 DOI: 10.18632/oncotarget.23423] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
164 Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120. [PMID: 21787417 DOI: 10.1186/1479-5876-9-120] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
165 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-78] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 7.6] [Reference Citation Analysis]
166 Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 2021;3:100215. [PMID: 33392490 DOI: 10.1016/j.jhepr.2020.100215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
167 Zhao L, Yang Y, Ma B, Li W, Li T, Han L, Zhang Y, Shang YM, Lin H, Gao Q. Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. J Oncol 2019;2019:6454989. [PMID: 31662753 DOI: 10.1155/2019/6454989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
168 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
169 Liao W, Huang G, Liao Y, Yang J, Chen Q, Xiao S, Jin J, He S, Wang C. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget 2014;5:10271-9. [PMID: 25431949 DOI: 10.18632/oncotarget.2082] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
170 Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int 2016;36:1196-205. [PMID: 26901163 DOI: 10.1111/liv.13096] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
171 Jia GS, Feng GL, Li JP, Xu HL, Wang H, Cheng YP, Yan LL, Jiang HJ. Using receiver operating characteristic curves to evaluate the diagnostic value of the combination of multislice spiral CT and alpha-fetoprotein levels for small hepatocellular carcinoma in cirrhotic patients. Hepatobiliary Pancreat Dis Int 2017;16:303-9. [PMID: 28603099 DOI: 10.1016/s1499-3872(17)60018-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
172 Zhao LY, Huo RR, Xiang X, Torzilli G, Zheng MH, Yang T, Liang XM, Huang X, Tang PL, Xiang BD, Li LQ, You XM, Zhong JH. Hepatic resection for elderly patients with hepatocellular carcinoma: a systematic review of more than 17,000 patients. Expert Rev Gastroenterol Hepatol. 2018;12:1059-1068. [PMID: 30145919 DOI: 10.1080/17474124.2018.1517045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
173 Jin J, Zhu P, Liao Y, Li J, Liao W, He S. Elevated preoperative aspartate aminotransferase to lymphocyte ratio index as an independent prognostic factor for patients with hepatocellular carcinoma after hepatic resection. Oncotarget 2015;6:19217-27. [PMID: 26057470 DOI: 10.18632/oncotarget.4265] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
174 Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller S, Bockisch A, Gerken G, Yang D, Schlaak JF. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS One 2013;8:e82225. [PMID: 24367506 DOI: 10.1371/journal.pone.0082225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
175 Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. Hepatol Res 2015;45:415-22. [PMID: 24861870 DOI: 10.1111/hepr.12365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
176 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 Cammà C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int 2009;29:478-80. [PMID: 19323777 DOI: 10.1111/j.1478-3231.2009.01994.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
178 Hui TC, Pua U. Arterial Portography during Transarterial Chemoembolization: Still a Necessity in the Age of Contrast-enhanced Cross-sectional Imaging? Journal of Vascular and Interventional Radiology 2014;25:41-6. [DOI: 10.1016/j.jvir.2013.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
179 Liu Y, Xue D, Zhang X, Gao F, Sun L, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. Biomed Res Int 2020;2020:1473718. [PMID: 32149077 DOI: 10.1155/2020/1473718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51. [PMID: 20175032 DOI: 10.1055/s-0030-1247131] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 19.3] [Reference Citation Analysis]
181 Long XD, Yao JG, Zeng Z, Ma Y, Huang XY, Wei ZH, Liu M, Zhang JJ, Xue F, Zhai B. Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma. Hepatology. 2013;58:171-181. [PMID: 23390017 DOI: 10.1002/hep.26311] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
182 Zeng J, Zeng J, Liu J, Zeng J. Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma. Liver Int 2021. [PMID: 34416088 DOI: 10.1111/liv.15042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Lee CW, Chan KM, Tsai HI, Hsieh YC, Lin CY, Kuo YC, Hsu HY, Yu MC. Hepatic resection for hepatocellular carcinoma in the octogenarian: is it justified? Aging (Albany NY) 2019;11:1537-50. [PMID: 30867335 DOI: 10.18632/aging.101854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
184 Ng KYY, Wong LWJ, Ang AJS, Tan SH, Choo SP, Tai DW, Lee JJX. Real‐world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia‐Pac J Clin Oncol 2021;17. [DOI: 10.1111/ajco.13454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
185 Yu JI, Park HC, Lim DH, Park W, Yoo BC, Paik SW, Koh KC, Lee JH. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci. 2011;26:1014-1022. [PMID: 21860551 DOI: 10.3346/jkms.2011.26.8.1014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
186 Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729-736. [PMID: 26604044 DOI: 10.1111/liv.13029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
187 Hayashi A, Yamauchi N, Shibahara J, Kimura H, Morikawa T, Ishikawa S, Nagae G, Nishi A, Sakamoto Y, Kokudo N, Aburatani H, Fukayama M. Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One 2014;9:e91330. [PMID: 24614346 DOI: 10.1371/journal.pone.0091330] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
188 汪晋, 马金良, 许戈良, 荚卫东, 余继海, 葛永胜, 曹堃. 原发性肝癌手术预后的相关影响因素. 世界华人消化杂志 2014; 22(35): 5526-5532 [DOI: 10.11569/wcjd.v22.i35.5526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
190 Qiu X, Hu B, Huang Y, Deng Y, Wang X, Zheng F. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance. Dig Dis Sci 2016;61:149-57. [DOI: 10.1007/s10620-015-3878-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
191 Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328-2338. [PMID: 22459764 DOI: 10.1016/j.ejca.2012.03.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 6.3] [Reference Citation Analysis]
192 Fu YP, Ni XC, Yi Y, Cai XY, He HW, Wang JX, Lu ZF, Han X, Cao Y, Zhou J, Fan J, Qiu SJ. A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article. Medicine (Baltimore) 2016;95:e2784. [PMID: 26886627 DOI: 10.1097/MD.0000000000002784] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
193 Su C, Chau G, Hung H, Yeh Y, Lei H, Hsia C, Lai C, Lin H, Wu J. Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. Ann Surg Oncol 2015;22:2253-61. [DOI: 10.1245/s10434-014-4221-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
194 Zhu X, Yuan J, Zhu T, Li Y, Cheng X. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS J 2016;283:3739-54. [DOI: 10.1111/febs.13839] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 16.0] [Reference Citation Analysis]
195 Lee YH, Hsia CY, Hsu CY, Huang YH, Lin HC, Huo TI. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg 2013;37:1348-55. [PMID: 23467925 DOI: 10.1007/s00268-013-1978-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
196 Jin K, Lu M, Liu F, Gu J, Du X, Xing B. N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surgery 2013;153:518-25. [DOI: 10.1016/j.surg.2012.08.067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
197 Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, Lu JH, Wu FQ, Lau WY, Wu MC, Yang T, Shen F. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014;38:947-57. [PMID: 24258262 DOI: 10.1007/s00268-013-2365-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
198 Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology 2017;93:233-42. [PMID: 28683459 DOI: 10.1159/000455957] [Reference Citation Analysis]
199 Conticchio M, Inchingolo R, Delvecchio A, Laera L, Ratti F, Gelli M, Anelli F, Laurent A, Vitali G, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, di Benedetto F, de'Angelis N, Briceño J, Rampoldi A, Adam R, Cherqui D, Aldrighetti LA, Memeo R. Radiofrequency ablation vs surgical resection in elderly patients with hepatocellular carcinoma in Milan criteria. World J Gastroenterol 2021; 27(18): 2205-2218 [PMID: 34025074 DOI: 10.3748/wjg.v27.i18.2205] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Liu Y, Sun L, Gao F, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Feng Y, Jiang Y, Wang X. A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13536. [PMID: 30544459 DOI: 10.1097/MD.0000000000013536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
201 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
202 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
203 Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, Shen F, Wu MC. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38:683-691. [PMID: 22621971 DOI: 10.1016/j.ejso.2012.04.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
204 Mukthinuthalapati VVPK, Wang Y, Abu Omar Y, Syed M, Attar B. Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital. J Gastrointest Oncol 2018;9:833-9. [PMID: 30505582 DOI: 10.21037/jgo.2018.06.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
205 Yoo JJ, Chung GE, Lee JH, Nam JY, Chang Y, Lee JM, Lee DH, Kim HY, Cho EJ, Yu SJ, Kim YJ, Yoon JH; Seoul Liver Group. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Res Treat 2018;50:366-73. [PMID: 28521494 DOI: 10.4143/crt.2017.126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]